| Title | Author | Article Type |
|---|---|---|
| High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission | I. Morozov, T. P. Monath, D. A. Meekins et al | Original Article |
| Title | Author | Article Type |
|---|---|---|
| Delayed recognition of Ebola virus disease is associated with longer and larger outbreaks | M. J. Matson, D. S. Chertow & V. J. Munster | Review |
| Title | Author | Article Type |
|---|---|---|
| GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus | D. Chen, Z. Hou, D. Jiang et al | Original Article |
| Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription | J. Chen, Z. He, Y. Yuan et al | Original Article |
| Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques | X. Yang, X. Wang, Y. Song et al | Original Article |
| Lessons to be learned from the ebolavirus outbreak in West Africa | H. D. Klenk | Commentary |
| Title | Author | Article Type |
|---|---|---|
| Determining the effect of different environmental conditions on Ebola virus viability in clinically relevant specimens | B. Palyi, N. Magyar, J. Henczko et al | Original Article |
| Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism | W. Seesuay, S. Jittavisutthikul, N. Sae-lim et al | Original Article |
| Title | Author | Article Type |
|---|---|---|
| T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection | C. L. Cooper, K. A. Martins, S. M. Stronsky et al | Original Article |
| Title | Author | Article Type |
|---|---|---|
| A sensitive and specific point-of-care detection assay for Zaire Ebola virus | X. A. Zhang, S. Li, J. Ching et al | Letter |
| Title | Author | Article Type |
|---|---|---|
| Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs | J. Kouznetsova, W. Sun, C. Martínez-Romero et al | Original Article |
| The Chinese Ebola Diagnostic and Treatment Center in Liberia as a model center | X. Xu, J. Huang, H. Yang et al | Letter |
| Title | Author | Article Type |
|---|---|---|
| The quest for effective Ebola treatment: Ebola VP35 is an evidence-based target for dsRNA drugs | W. M. Mitchell & W. A. Carter | Letter |
| Title | Author | Article Type |
|---|---|---|
| Traditional passive immune therapy for emerging Ebola infection | P. J. Lachmann | News & Views |
| Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola | S. Lu | Commentary |